

SOUTH DAKOTA BOARD OF REGENTS ACADEMIC AFFAIRS FORMS

New Course Request

	Pharmacy & Allied Health Professions/Pharmaceutical	
SDSU	Sciences	
Institution	Division/Department	
Dennis D. Hedge	-	2/7/2018
Institutional Approval Signature		Date
institutional rippi ovar	, ignature	Dute
Continue 1 Comment		

Section 1. Course Title and Description		
Prefix & No.	Course Title	Credits
PHA 452	Pathophysiology, Pharmacology & Toxicology III	4

*short title for use in Colleague: Pathophys, Pharmacol, Tox III

Course Description

Continuation of Pathophysiology, Pharmacology & Toxicology II. Pathophysiology of common and significant diseases, the pharmacology of medications used in treatment of those diseases, and basic principles of prevention and treatment of drug overdoses and poisonings.

Pre-requisites or Co-requisites

Prefix & No.	Course Title	Pre-Req/Co-Req?
PHA 353	Pathophysiology, Pharmacology & Toxicology II	Pre-Req

Registration Restrictions

None

SDSU Catalog Note: P2 year standing.

Section 2. Review of Course

2.1. Was the course first offered as an experimental course?

 \boxtimes Yes (if yes, provide the course information below) \Box No

2.2. Will this be a unique or common course?

⊠ Unique Course

Prefix & No.	Course Title	Credits
PHA 320/ NURS 323	Introduction to Pathophysiology	3
NURS 321	Pharmacology	3

Provide explanation of differences between proposed course and existing system catalog courses below:

Pathophysiology content is covered in PHA 320/NURS 323 Introduction to Pathophysiology. The proposed new course is an integrated course including pathophysiology, pharmacology, and toxicology. The integrated nature of the course distinguishes the proposed class from NURS 323. PHA 320 will be deleted due to the introduction of the integrated course. The intent of the integration is to allow greater depth of content coverage and improved student learning. There is a pharmacology course for nursing students (NURS 321) in the inventory. This course is focused on nursing applications related to drug administration, is only a one-semester three credit course, and is not integrated. Therefore, it does not have the required breadth and depth of pharmacology content required for the Doctor of Pharmacy program. The proposed Pathophysiology, Pharmacology, and Toxicology course sequence is an overall four-semester course sequence with a fully integrated design which distinguishes it from NURS 321.

Common Course Indicate universities that are proposing this common course:

Curriculum Forms, New Course Request (Last Revised 01/2017)

\Box BHSU \Box DSU \Box NSU

 \Box SDSMT \Box SDSU \Box USD

Section 3. Other Course Information

3.1. Are there instructional staffing impacts?

X No. Replacement of PHA 443 Pharmacology II, 4 cr

(course prefix, course number, name of course, credits)

Effective date of deletion: 1/1/2020

This course involves the integration of content from multiple separate courses. The same faculty involved in teaching the currently separate courses will teach the integrated course series.

🖾 No

3.2. Existing program(s) in which course will be offered: BS in Pharmaceutical Sciences/PharmD

3.3. Proposed instructional method by university: R-Lecture

- 3.4. **Proposed delivery method by university:** 001 Face to face, Term based
- **3.5.** Term change will be effective: Fall 2018

3.6. Can students repeat the course for additional credit?

□ Yes, total credit limit:

3.7. Will grade for this course be limited to S/U (pass/fail)?

🗆 Yes 🖾 No

3.8. Will section enrollment be capped?

 \boxtimes Yes, max per section: 80 \square No

3.9. Will this course equate (i.e., be considered the same course for degree completion) with any other unique or common courses in the common course system database in Colleague and the Course Inventory Report?

 \Box Yes \boxtimes No

3.10. Is this prefix approved for your university?

 \boxtimes Yes \square No

Section 4. Department and Course Codes (Completed by University Academic Affairs)

4.1. University Department Code: SPAHP

4.2. Proposed CIP Code: 51.2001

Is this a new CIP code for the university? \Box Yes \boxtimes No

NEW COURSE REQUEST Supporting Justification for On-Campus Review

Teresa Seefeldt	Teresa Seefeldt	9/25/2017
Request Originator	Signature	Date
Om Perumal	Om Perumal	10/30/2017
Department Chair	Signature	Date
Jane Mort	Jane Mort	10/30/2017
School/College Dean	Signature	Date

1. Provide specific reasons for the proposal of this course and explain how the changes enhance the curriculum.

The proposed course involves integration of content from four existing courses (PHA 320 Introduction to Pathophysiology, PHA 442 Pharmacology I, PHA 443 Pharmacology II, and PHA 444 Toxicology). The content from these courses is highly interrelated as understanding of the pathophysiology of disease is critical to understanding how drugs work to treat that disease and knowledge of pharmacology is critical to understanding the effects of poisonings and overdoses. By integrating the content into one course series, students should be better able to make the connections between the content areas with the goal of improving understanding

and retention. In addition, new student learning outcomes and expectations for pharmacy practice require a greater depth of knowledge in pathophysiology. Specifically, student pharmacists need to understand detailed mechanisms of disease processes to understand how the medications impact these mechanisms. Integration of the pathophysiology content with pharmacology and toxicology will allow for greater depth of coverage and help students make the connections between disease and drug mechanism of action.

- 2. Note whether this course is: \square Required \square Elective
- 3. In addition to the major/program in which this course is offered, what other majors/programs will be affected by this course? Currently, pathophysiology is offered as a joint course between nursing and pharmacy. With this change, the pharmacy students will take the integrated pathophysiology, pharmacology, and toxicology course series instead of the stand-alone pathophysiology course.
- 4. If this will be a dual listed course, indicate how the distinction between the two levels will be made.
 - NA
- 5. Desired section size 80
- 6. Provide qualifications of faculty who will teach this course. List name(s), rank(s), and degree(s).

Gudiseva Chandrasekher, PhD, Associate Professor of Pharmaceutical Sciences Shafiqur Rahman, PhD, Professor of Pharmaceutical Sciences

Teresa Seefeldt, PharmD, PhD, Associate Professor of Pharmaceutical Sciences

7. Note whether adequate facilities are available and list any special equipment needed for the course.

Adequate classroom facilities are available to teach this course. No special equipment is needed.

- Note whether adequate library and media support are available for the course. Library and media support resources are adequate for this course. No special resources are needed.
- 9. Will the new course duplicate courses currently being offered on this campus?

🗆 Yes 🖾 No

10. If this course may be offered for variable credit, explain how the amount of credit at each offering is to be determined.

NA